Method and System for Treating Non-Alcoholic Fatty Liver Disease
First Claim
Patent Images
1. A method for treating non-alcoholic fatty liver disease, comprising:
- providing to an individual in need thereof an effective amount of a composition comprising bacteria modified using a Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR-associated system (CRISPR-Cas) or Clustered Regularly Interspaced Short Palindromic Repeats from Prevotella and Francisella 1 (CRISPR/Cpf1) system so that the bacteria is able to produce desired levels of anti-bodies to oxidized low density lipoprotein (oxLDL).
1 Assignment
0 Petitions
Accused Products
Abstract
A method and system for treating non-alcoholic fatty liver disease (NAFLD) involves the modulation of the gut microbial of a person suffering from NAFLD, and in particular the provision of a probiotic therapy configured to reduce liver aminotransferases, total-cholesterol, TNF-α and to improve insulin resistance in NAFLD patients.
30 Citations
10 Claims
-
1. A method for treating non-alcoholic fatty liver disease, comprising:
- providing to an individual in need thereof an effective amount of a composition comprising bacteria modified using a Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR-associated system (CRISPR-Cas) or Clustered Regularly Interspaced Short Palindromic Repeats from Prevotella and Francisella 1 (CRISPR/Cpf1) system so that the bacteria is able to produce desired levels of anti-bodies to oxidized low density lipoprotein (oxLDL).
- View Dependent Claims (2)
-
3. A method for treating non-alcoholic fatty liver disease, comprising:
-
establishing in the gut of an individual a population of beneficial bacteria selected from the group consisting of Lactobacillus, Bifidobacterium, and Streptococcus species; and administering at least 6 grams per day of fiber to the individual to maintain the beneficial bacteria in the gut of the individual. - View Dependent Claims (4, 5, 6, 8, 9, 10)
-
-
7. A method for treating non-alcoholic fatty liver disease, comprising:
providing to an individual in need thereof an effective amount of a composition comprising modified L. reuteri bacteria, said L. reuteri bacteria modified using CRISPR-Cas and/or Cpf1 systems in a manner such that said bacteria are able to survive the conditions in the duodenum and jejunum of the small intestine of a human.
Specification